A Randomized, Patient and Investigator Blinded, Placebo Controlled, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With Non-alcoholic Steatohepatitis (NASH)
Phase of Trial: Phase II
Latest Information Update: 27 Jun 2017
At a glance
- Drugs LMB 763 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 06 Apr 2017 Planned End Date changed from 15 Feb 2018 to 18 Oct 2018.
- 06 Apr 2017 Planned primary completion date changed from 15 Feb 2018 to 18 Oct 2018.
- 13 Dec 2016 Status changed from not yet recruiting to recruiting.